Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.46 |
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477022 | 0.89 | RORC (0.60) | RORCL3MBTL1IDH1 | |
| SCHEMBL18477024 | 0.89 | RORC (0.64) | RORCIDH1 | |
| SCHEMBL20465159 | 0.85 | L3MBTL1 (0.56) | RORCL3MBTL1HCAR3IDH1HSD17B10 | |
| SCHEMBL20465151 | 0.85 | RORC (0.58) | RORCL3MBTL1IDH1 | |
| SCHEMBL29893492 | 0.77 | CSNK2A2 (0.43) | RORCL3MBTL1HCAR3HSD17B10 | |
| SCHEMBL20454463 | 0.75 | RORC (0.77) | RORC | |
| SCHEMBL20465152 | 0.75 | RPS6KB1 (0.55) | RORCIDH1 | |
| SCHEMBL14382629 | 0.70 | L3MBTL1 (0.59) | L3MBTL1HCAR3IDH1HSD17B10GAA | |
| SCHEMBL24015971 | 0.69 | HCAR3 (0.42) | RORCL3MBTL1HCAR3HSD17B10GAA | |
| SCHEMBL24015972 | 0.69 | HCAR3 (0.42) | RORCL3MBTL1HCAR3HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | RORC 2/4885L3MBTL1 4747/4885HCAR3 526/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RORC 2/4885L3MBTL1 4609/4885HCAR3 1455/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RORC 2/4885L3MBTL1 4609/4885HCAR3 1455/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | RORC 1/4885L3MBTL1 4634/4885HCAR3 1403/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | RORC 1/4885L3MBTL1 4728/4885HCAR3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.